COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma (TIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00200577
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : June 1, 2017
Information provided by (Responsible Party):
Nantes University Hospital

Brief Summary:
The objective of this multicentric Phase III study is to confirm the results of the phase I-II study (Dreno B & Al. Cancer Immunol Immunother 2002; 51: 539-456) which demonstrated the preventive effect of a treatment by TIL (Tumor Infiltrating Lymphocytes) combined with IL2 (Interleukin 2; low dose injected subcutaneously) on the metastatic relapse in the stage III melanoma patients with only one invaded lymphnode.

Condition or disease Intervention/treatment Phase
Melanoma Drug: TIL + IL2 Phase 3

Detailed Description:
In this open, multicentric (Grenoble, Montpellier, Nantes, Angers, Caen, Le Mans, Poitiers, Rennes, Tours) randomized study, selected patients with only one invaded lymphnode confirmed by anatomopathological exam will be randomized to one of the following arms: 1-Control group: patients of this group will not receive any treatment and will have the same clinical follow-up as the treated group. 2- TIL-IL2 group: treated patients will receive two injections of TIL combined with IL2. Tumor Infiltrating Lymphocytes will be obtained from a small piece of tumour tissue removed from the invaded lymphnode after surgery. TIL will be grown in larger number in laboratory during 6 weeks. Patients randomized in treatment arm will receive two injection of TIL (the first about 6 and the second about 10 weeks post-surgery). Administration of TIL will be combined with a low dose of IL2 (6 million U.I. per day) injected subcutaneously from J1 to J5 and J8 to J12 following the day of TIL infusion. The same dose and duration of IL2 treatment will be used for the second injection of TIL performed one month later. After 2 months adjuvant therapy, patients received no other treatment. Only a regular follow-up was performed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: TIL (Tumor Infiltrating Lymphocytes) and IL2 (Interleukin 2) Versus Abstention as Adjuvant Treatment in Melanoma With Only One Invaded Lymphnode After Lymphnodes Excision
Study Start Date : May 2005
Actual Primary Completion Date : March 2012
Actual Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: TIL+IL2
Drug: TIL + IL2
Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12

No Intervention: control
Patients are not treated

Primary Outcome Measures :
  1. Determination of the duration of the relapse-free interval. [ Time Frame: 5 years ]
  2. Physical examination, every 2 months until M18 then every 3 months until M36 then every 4 months up to 5 years, then once per year with a clinical examination only. [ Time Frame: every 2 months until M18then every 3 months until M36 then every 4 months up to 5 years ]
  3. Abdominal echography will be performed at the screening visit, M4, M8, M12 and then every 6 months until 5ans. [ Time Frame: M4, M8, M12 and then every 6 months until 5ans. ]
  4. CT-Scan will be performed before the first administration of study treatment (at the time of screening visit), every 6 months during 2 years and then every years up to 5 years. [ Time Frame: every 6 months during 2 years and then every years up to 5 years. ]

Secondary Outcome Measures :
  1. Determine of overall survival [ Time Frame: 5 years ]
  2. To define safety and toxicity of TIL/IL2 treatment [ Time Frame: 5 years ]
  3. Evaluation of immunological responses [ Time Frame: M0, J56, M12 ]
  4. Analysis of the clinical, biological and histological factors on the survival of the patients [ Time Frame: at inclusion and each month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Melanoma stage III (regional lymph node recurrence). Will be selected the patients with only one invaded lymph node confirmed by anatomopathological exam after lymph nodes excision.
  • Absence of visceral metastases verified by physical examination, chest radiography, liver echography and brain-chest-liver CT-Scan.
  • Age < 75 years, both genders
  • ECOG 0-2, Karnofsky > 80%.
  • Negative pregnancy test performed at the screening visit for fertile women.
  • The potentially fertile women must use an oral contraception or an intra-uterine device (IUD) until three months following the last injection of the study treatment.
  • The patients must have fully recovered from surgery.
  • HIV 1/2: The patients must be negative for antibodies HIV 1 and HIV 2 and for Ag P24 or DGV HIV.
  • HBV: The patients must be negative for the antigen, but can be positive for the antibodies but with a negative DNA PCR.
  • HCV: The patients must be negative for the antibodies.
  • HTLV ½: The patients must be negative for the antibodies.
  • Following laboratory results:

    • Hemoglobin: ≥ 10 g/dl
    • WBC: ≥ 4000/µl
    • Lymphocytes: ≥ 700/µl
    • Platelet count: ≥ 100.000/µl
    • Serum creatinine: < 2.0 mg/dl or £ 177 mmol/l
    • Serum Bilirubin: < 2.0 mg/dl or £ 34.2 mmol/l
    • ASAT and ALAT: < 2.5 x the upper limit of normal.

Exclusion criteria:

  • Patient with more than one invaded lymph node confirmed by anatomopathological exam.
  • Presence of melanoma metastases discovered by clinical or radiological examination at the screening visit.
  • Patients must not have received any Chemotherapy, immunotherapy or radiotherapy within the preceding 4 weeks (6 weeks since prior nitrosurea and mitomycin C therapies).
  • Presence of cardiac affections (congestive cardiac insufficiency, coronaropathy, not controlled HTA).
  • Any serious active medical illnesses, for example: Active systemic infections requiring of antibiotics, coagulation disorders or any other condition which requires concomitant medications not allowed during this study.
  • Presence of the second active cancer other than surgically cured non-melanoma skin cancer or cervical carcinoma in-situ.
  • Any affection requiring a systemic corticotherapy or a treatment by Interferon A.
  • Any active auto-immune disease including the insulin-dependent diabetes or a immunodeficiency. The vitiligo is not an exclusion criteria.
  • Thyroid dysfunction not responsive to therapy.
  • Positive Serology for HIV, HVB, HVC or HTLV1/2.
  • Woman pregnant or nursing or without an effective contraception.
  • Incapacity to give written consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00200577

Layout table for location information
CHU Angers
Angers, France
CHU Caen
Caen, France
Grenoble University Hospital
Grenoble, France
CH Le Mans
Le Mans, France
Montpellier University Hospital
Montpellier, France
Nantes University Hospital
Nantes, France, 44093
CHU Poitiers
Poitiers, France
CHU Rennes
Rennes, France
CHRU Tours
Tours, France
Sponsors and Collaborators
Nantes University Hospital
Layout table for investigator information
Principal Investigator: Brigitte DRENO, MD Nantes University Hospital
Layout table for additonal information
Responsible Party: Nantes University Hospital Identifier: NCT00200577    
Other Study ID Numbers: BRD/04/01-D
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: June 1, 2017
Last Verified: May 2017
Keywords provided by Nantes University Hospital:
Adjuvant therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas